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Ischaemic heart disease resulting from rupture of 
atherosclerotic plaques is a major cause of death world-
wide. Precisely why a plaque ruptures remains a mystery. 
However, in The Lancet, Nikhil Joshi and colleagues’ 
ﬁ ndings1 suggest that we are close to being able to 
detect when rupture is about to occur.
The simple and inexpensive ¹⁸F-sodium ﬂ uoride 
(¹⁸F-NaF) PET radioisotope, used for 30 years to image 
bone formation, was found to signify metabolically 
active calciﬁ cation in the aorta by Derlin and colleagues2 
and in the coronary arteries by Beheshti,3 Dweck,4 and 
Li,5 and their colleagues. In their landmark article, Joshi 
and coworkers move this nascent ﬁ eld much farther 
forward.1 They prospectively studied 40 patients with 
recent myocardial infarction (mean 8 days earlier) with 
invasive coronary angiography, CT coronary angiography, 
coronary calcium scoring, and cardiac gated PET-CT with 
¹⁸F-NaF and ¹⁸F-ﬂ uorodeoxyglucose (¹⁸F-FDG). Using 
invasive coronary angiography as the gold standard 
for determining the culprit plaque, the area of greatest 
¹⁸F-NaF uptake in the coronary arteries localised the 
plaque in 37 of 40 patients (maximum tissue-to-back-
ground ratio in the culprit plaque 1·66 [1·40–2·25] vs 
highest non-culprit plaque 1·24 [1·06–1·38]). By contrast, 
interpretation of ¹⁸F-FDG PET-CT images in the same 
cohort was technically diﬃ  cult because of the frequent 
overlap of myocardial ¹⁸F-FDG uptake with the adjacent 
coronary arteries. Of the 55% of vascular territories that 
were interpretable by ¹⁸F-FDG, only a weak correlation 
was seen with culprit plaque identiﬁ cation. 
A second cohort of 40 patients with stable angina 
underwent the same imaging tests and an intracoronary 
ultrasound. 18 patients had one or more plaques with 
high ¹⁸F-NaF uptake, deﬁ ned as at least 25% greater than 
a proximal reference lesion. Intracoronary ultrasound 
identiﬁ ed that microcalciﬁ cation, necrotic core size, and 
positive remodelling correlated strongly with plaques of 
high ¹⁸F-NaF activity.
Histological correlation was assessed in a third cohort 
of nine patients who underwent carotid endarterectomy 
at a mean of 17 days after clinical symptoms. Ex-vivo 
PET-CT was done on the removed carotid atherosclerotic 
tissue. Macroscopic plaque rupture was present in each 
patient, all localised to areas of high ¹⁸F-NaF uptake. 
Plaques with increased ¹⁸F-NaF uptake had substantially 
larger necrotic cores, more cell death and macrophage 
inﬁ ltration, and, as measured by alkaline phosphatase 
and osteocalcin staining, more active calciﬁ cation than 
those that did not.
With the strong in-vivo correlates of coronary plaque 
rupture seen on intracoronary ultrasound in patients 
with stable angina, and histological conﬁ rmation of 
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plaque rupture in atherosclerotic carotid tissue with high 
¹⁸F-NaF activity, the authors can indeed state that of 40 
patients with recent myocardial infarction (37 men, three 
women), plaque rupture can be detected non-invasively.
Now that we can detect plaque rupture, should 
we? Although the radioisotope ¹⁸F-NaF and PET-CT 
equipment are readily available in the developed world, 
much research needs to be done before the technique 
can become a viable clinical option. Just because a plaque 
at risk for rupture can be identiﬁ ed does not mean that 
we know what to do with this information. Prospective 
trials are needed to establish the frequency with which 
high ¹⁸F-NaF plaques rupture, and the timing of rupture. 
Also, does plaque rupture result in events or simply the 
rupture and healing cycle believed to result in a stepwise 
increase in plaque stenosis? If such trials are positive, 
what will we do with the information? Of Joshi and 
colleagues’ 40 patients with stable angina, nearly all were 
on antiplatelet agents and 36 were taking statins. Despite 
this therapy, 18 patients had at least one plaque with 
high ¹⁸F-NaF uptake. However, the ability to assess and 
potentially quantitatively measure plaque at high risk of 
rupture as a continuous variable (by maximum standard 
uptake value) creates a new world of opportunity for the 
investigation of pharmacological and device therapy.
The technique holds greater promise in populations 
with myocardial infarction and acute coronary 
syndrome than in more stable patients. Earlier work 
by Joshi and colleagues, for example, found a strong 
correlation between patients with high NaF plaques and 
those with the more easily and inexpensively obtained 
total Agatston coronary calcium score.4
The technique also creates the opportunity to 
better assess the commonly accepted belief that most 
myocardial infarctions are caused by rupture of previously 
non-obstructive plaques. The underpinnings of this 
theory are derived from coronary angiography that is 
done distant from the index myocardial infarction.6,7 
Narula and colleagues8 and others have questioned this 
assumption. The predictive value for increasing non-
fatal myocardial infarction and cardiac death consistently 
seen in studies of increasing ischaemia, as assessed 
by myocardial perfusion imaging,9 and worsening 
obstructive disease by coronary CT10 and invasive 
angiography, are also inconsistent with this assumption.
Questions to be answered include: how best to 
use information derived from an assessment of 
inﬂ ammation by ¹⁸F-FDG and active calciﬁ cation by 
¹⁸F-NaF. In large vessels without adjacent areas of 
intense ¹⁸F-FDG activity, ¹⁸F-FDG assessment is much 
less handicapped by overlapping structures compared 
with the coronary arteries. How do Joshi and colleagues’ 
ﬁ ndings apply to women, in whom plaque erosion 
is a much more common mechanism of myocardial 
infarction than in men? How do the ﬁ ndings apply to 
patients with diabetes? Does coronary artery bypass 
graft biology diﬀ er with respect to ¹⁸F-NaF activity? 
Do high ¹⁸F-NaF plaques in the carotid and other 
cerebrovascular vessels predict stroke and transient 
ischaemic attack? Joshi and colleagues and earlier 
pioneers have identiﬁ ed a new and hopefully fruitful 
frontier in nuclear cardiology and atherosclerotic 
coronary imaging.
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